Sugi Predict

Sugi Predict / Compounds / SCHEMBL6094889

SCHEMBL6094889

SCHEMBL6094889

Cc1nc(Oc2ccccc2)c(N)c(NCCNC(=O)OC(C)(C)C)c1C

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 2/20 0.45
▸ BRD4 O60885 4/20 0.42
▸ MALT1 Q9UDY8 1/20 0.42
▸ CKS1B P61024 1/20 0.40
▸ SKP1 P63208 1/20 0.40
▸ SKP2 Q13309 1/20 0.40
▸ ADORA3 P0DMS8 1/20 0.39
▸ ADORA2A P29274 1/20 0.39
▸ ADORA1 P30542 1/20 0.39
▸ IDO1 P14902 1/20 0.38
▸ ACHE P22303 1/20 0.37
▸ LATS1 O95835 1/20 0.37
▸ ATR Q13535 1/20 0.37
▸ NQO2 P16083 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6095098 0.94 BRD4 (0.44) BCHEBRD4CKS1BSKP1SKP2
SCHEMBL6097248 0.94 BRD4 (0.44) BCHEBRD4ADORA2AADORA1
SCHEMBL4775915 0.92 ADORA2A (0.41) BCHEBRD4MALT1CKS1BSKP1
SCHEMBL1232835 0.88 ALDH1A1 (0.36) —
SCHEMBL6096324 0.84 BCHE (0.42) BCHEBRD4MALT1CKS1BSKP1
SCHEMBL1232939 0.82 TOP2A (0.37) —
SCHEMBL28753431 0.82 TOP2A (0.37) BCHEACHE
SCHEMBL6095408 0.79 BRD4 (0.42) BCHEBRD4
SCHEMBL6095926 0.79 BRD4 (0.41) BCHEBRD4CKS1BSKP1SKP2
SCHEMBL27609571 0.79 BCHE (0.36) BCHEBRD4ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7888349-B2 Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-02-15 — — US disclosed
US-20070167476-A1 Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds 3M INNOVATIVE PROPERTIES COMPANY 2007-07-19 — — US disclosed
US-7098221-B2 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-08-29 — — US disclosed
US-20050282854-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2005-12-22 — — US disclosed
US-6969722-B2 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-11-29 — — US disclosed
US-6903113-B2 Urea substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-06-07 — — US disclosed
US-6878719-B2 Sulfonamido substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-04-12 — — US disclosed
US-20040186128-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-09-23 — — US disclosed
EP-1453829-A1 SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2004-09-08 — — EP disclosed
EP-1451187-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2004-09-01 — — EP disclosed
US-20030195209-A1 Urea substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-10-16 — — US disclosed
US-20030186949-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-10-02 — — US disclosed
US-20030176458-A1 Urea substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-09-18 — — US disclosed
US-20030162806-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-08-28 — — US disclosed
WO-2003050117-A1 SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 — — WO disclosed
WO-2003050118-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 — — WO disclosed
WO-2003050119-A2 UREA SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 — — WO disclosed
US-6545017-B1 Inducing cytokine biosynthesis; treating a viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2003-04-08 — — US disclosed
US-6545016-B1 Inducing cytokine biosynthesis; treating a viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2003-04-08 — — US disclosed
US-6525064-B1 Immune response modifiers; can induce the biosynthesis of various cytokines; 3M INNOVATIVE PROPERTIES COMPANY 2003-02-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186128-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG BCHE 4341/4885BRD4 57/4885MALT1 513/4885
US-20030176458-A1 Urea substituted imidazopyridines EIF2AK2, UMPS, IRF3 BCHE 3465/4885BRD4 463/4885MALT1 1278/4885
US-20030195209-A1 Urea substituted imidazopyridines EIF2AK2, UMPS, IRF3 BCHE 3465/4885BRD4 463/4885MALT1 1278/4885
US-20050282854-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG BCHE 4341/4885BRD4 57/4885MALT1 513/4885
US-20070167476-A1 Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds IL4, IL2, IL5 BCHE 2817/4885BRD4 38/4885MALT1 349/4885
US-20030162806-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG BCHE 4341/4885BRD4 57/4885MALT1 513/4885
US-20030186949-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG BCHE 4341/4885BRD4 57/4885MALT1 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.